Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.50
    +1.40 (+2.09%)

    Market Cap: $16.37B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Exelixis Inc (EXEL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Exelixis (EXEL) has a market cap of $16.37B and an enterprise value of $16.09B. Its share count is down 7.99% from a year earlier. It kept 35.33% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 1.72% below the market cap, as cash exceeds debt.

    Market Cap$16.37B
    Enterprise Value$16.09B
    Latest price (Nov 17, 2026)$68.50

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 2.91% in the quarter ended Jun 30, 2026 and shrank 6.88% a year over 2 years.

    Shares Outstanding250.81M
    Shares Change (YoY)-7.99%
    Shares Change (QoQ)-2.91%
    Share Count Growth (2Y CAGR)-6.88%

    Valuation Ratios

    Sales and book value multiples are 7.1x and 9.3x. Its year-end P/E ranged from 13.8x to 59.6x from 2017 to 2025.

    P/E Ratio19.7x
    Forward P/E19.6x
    P/S Ratio7.1x
    Forward P/S6.4x
    P/B Ratio9.3x
    P/TBV Ratio9.7x
    P/FCF Ratio14.7x
    P/OCF Ratio13.8x
    PEG Ratio2.4

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 16.9x EBITDA and 14.4x free cash flow.

    EV / Earnings18.7x
    EV / Sales6.6x
    EV / EBITDA16.9x
    EV / FCF14.4x

    Price Statistics

    The stock is up 64.47% over 52 weeks and trades 9.32% above its 50-day average.

    Beta (1Y)0.63
    52-Week Change+64.47%
    1-Month Change+9.29%
    3-Month Change+25.94%
    6-Month Change+40.74%
    5-Year Change+222.59%
    10-Year Change+555.24%
    Total Return (1Y)+64.47%
    Total Return (3Y CAGR)+47.99%
    Total Return (5Y CAGR)+31.42%
    Return vs SPY (1Y)+49.05%
    Max Drawdown (1Y)-12.59%
    Max Drawdown (3Y)-25.34%
    Sharpe Ratio (1Y)1.41
    Correlation with SPY (1Y)0.26
    50-Day Average$62.66
    200-Day Average$52.50
    52-Week Range$39.71 to $73.69
    RSI (14 Days)55.8
    Average Volume (20 Days)2.90M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.46x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.46x
    Quick Ratio3.38x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 46.68% over the last 12 months, against a 5-year average of 17.28%.

    Return on Equity (ROE)46.68%
    Return on Assets (ROA)34.50%
    ROE (5Y Average)17.28%
    ROA (5Y Average)13.40%
    ROIC (5Y Average)33.55%
    Asset Turnover0.94x
    Inventory Turnover3.10x
    Receivables Turnover7.48x
    Cash Conversion Cycle32 days

    Taxes

    Income tax took 16.89% of pretax income over the last 12 months.

    Income Tax (TTM)$174.84M
    Effective Tax Rate16.89%

    Scores

    EXEL has an Altman Z-Score of 18.39, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score18.39
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.44B over the last 12 months is up 9.23% from the 12 months before.

    Revenue$2.44B
    Revenue Growth (YoY)+9.23%
    Gross Profit$2.35B
    Operating Income$971.51M
    Pretax Income$1.04B
    Net Income$860.62M
    Reported EPS (TTM)$3.48

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 73.90% of the $2.49B in total assets.

    Cash and Equivalents$281.45M
    Total Debt$0
    Net Cash$281.45M
    Net Cash Per Share$1.12
    Working Capital$888.89M
    Shareholder Equity$1.84B
    Book Value Per Share$7.35
    Tangible Book Value$1.78B
    Tangible Book Per Share$7.10
    Total Assets$2.49B
    Total Liabilities$650.47M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $10.96M of capital spending, operating cash flow left $1.17B of free cash flow.

    Operating Cash Flow$1.18B
    Capital Expenditures$10.96M
    Free Cash Flow$1.17B
    FCF Per Share$4.73
    Depreciation and Amortization$28.30M
    Share Repurchases$1.11B

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 39.88%, against a 5-year average of 21.46%.

    Gross Margin96.48%
    Operating Margin39.88%
    Pretax Margin42.51%
    Net Margin35.33%
    FCF Margin48.13%
    Gross Margin (5Y Average)96.33%
    Operating Margin (5Y Average)21.46%
    Net Margin (5Y Average)19.31%

    Growth

    Revenue grew 12.93% a year over 3 years, and EPS 55.61% a year.

    Revenue Growth (3Y CAGR)+12.93%
    Revenue Growth (5Y CAGR)+18.63%
    EPS Growth (3Y CAGR)+55.61%
    EPS Growth (5Y CAGR)+37.88%
    FCF Growth (3Y CAGR)+37.77%
    FCF Growth (5Y CAGR)+37.43%
    Operating Income Growth (3Y CAGR)+62.98%
    Book Value Per Share Growth (2Y CAGR)+2.97%
    Tangible Book Per Share Growth (2Y CAGR)+2.90%

    Revenue and profit by year

    Dividends and Yields

    EXEL does not pay a dividend. Its free cash flow yield is 6.82%.

    Earnings Yield5.08%
    FCF Yield6.82%
    Buyback Yield6.29%
    Shareholder Yield6.29%

    Peer Position

    Against 3 similar companies, EXEL has the 3rd highest P/E.

    P/E Ratio19.7x vs 26.4x median
    P/S Ratio7.1x vs 15.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+9.23% vs +86.87% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 11.34% and EPS growth at 17.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+11.34%
    EPS Growth Forecast (2Y CAGR)+17.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EXEL

    What is EXEL's market cap?

    Exelixis has a market cap of $16.37B. Its enterprise value, which adds debt and subtracts cash, is $16.09B.

    What is EXEL's P/E ratio?

    Exelixis has a trailing P/E ratio of 19.7x and a forward P/E of 19.6x.

    How many shares of EXEL are outstanding?

    Exelixis has 250.81M shares outstanding. The count is down 7.99% from a year earlier.

    Does EXEL pay a dividend?

    No. Exelixis does not pay a dividend.

    How much debt does EXEL have?

    Exelixis has $0 of total debt and $281.45M of cash and equivalents, a net cash position of $281.45M.